12/5
07:21 am
kura
Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
12/4
08:12 am
kura
Kura Oncology: A Cautious Buy [Seeking Alpha]
Low
Report
Kura Oncology: A Cautious Buy [Seeking Alpha]
12/3
07:02 pm
kura
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]
Low
Report
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]
12/3
08:32 am
kura
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
Medium
Report
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
12/2
06:42 pm
kura
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data [Seeking Alpha]
Medium
Report
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data [Seeking Alpha]
12/2
08:02 am
kura
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Low
Report
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
11/25
05:16 pm
kura
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
Low
Report
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
11/25
05:21 am
kura
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed [Yahoo! Finance]
Medium
Report
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed [Yahoo! Finance]
11/24
07:02 am
kura
Kura Oncology (NASDAQ:KURA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Kura Oncology (NASDAQ:KURA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/19
05:24 pm
kura
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript [Seeking Alpha]
Medium
Report
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript [Seeking Alpha]
11/17
04:36 pm
kura
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Komzifti™ (ziftomenib) [Yahoo! Finance]
Medium
Report
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Komzifti™ (ziftomenib) [Yahoo! Finance]
11/14
12:31 pm
kura
Kura Oncology (NASDAQ:KURA) had its price target raised by analysts at UBS Group AG from $14.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Kura Oncology (NASDAQ:KURA) had its price target raised by analysts at UBS Group AG from $14.00 to $16.00. They now have a "buy" rating on the stock.
11/14
09:14 am
kura
Kura Oncology (NASDAQ:KURA) had its "outperform" rating reaffirmed by analysts at Wedbush.
Medium
Report
Kura Oncology (NASDAQ:KURA) had its "outperform" rating reaffirmed by analysts at Wedbush.
11/14
09:05 am
kura
Kura Oncology (NASDAQ:KURA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Kura Oncology (NASDAQ:KURA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/14
07:21 am
kura
Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy [Yahoo! Finance]
Medium
Report
Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy [Yahoo! Finance]
11/13
02:47 pm
kura
US FDA approves Kura-Kyowa's blood cancer therapy [Yahoo! Finance Canada]
Low
Report
US FDA approves Kura-Kyowa's blood cancer therapy [Yahoo! Finance Canada]
11/13
10:51 am
kura
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Medium
Report
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
11/12
04:05 pm
kura
Kura Oncology to Participate in Upcoming Investor Conference
Low
Report
Kura Oncology to Participate in Upcoming Investor Conference
11/7
07:30 am
kura
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/7
06:19 am
kura
Kura Oncology (NASDAQ:KURA) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Kura Oncology (NASDAQ:KURA) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/4
09:36 pm
kura
Kura Oncology (KURA): Persistent Losses Undercut Rapid 42.7% Revenue Growth Narrative [Yahoo! Finance]
Low
Report
Kura Oncology (KURA): Persistent Losses Undercut Rapid 42.7% Revenue Growth Narrative [Yahoo! Finance]
11/4
06:31 am
kura
Kura Oncology Reports Third Quarter 2025 Financial Results
Low
Report
Kura Oncology Reports Third Quarter 2025 Financial Results
11/3
04:02 pm
kura
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
Low
Report
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
11/3
09:14 am
kura
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
Medium
Report
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
10/28
04:01 pm
kura
Kura Oncology to Report Third Quarter 2025 Financial Results
Low
Report
Kura Oncology to Report Third Quarter 2025 Financial Results